These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1188705)

  • 1. The effect of Prodectin (pyridinolcarbamate) treatment of the circulation rate in obliterating arterial diseases of the lower extremities.
    Fényes G; Gótzy G; Fehrentheil L
    Ther Hung; 1975; 23(2):64-66. PubMed ID: 1188705
    [No Abstract]   [Full Text] [Related]  

  • 2. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 3. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 6. A clinical trial with pyridinolcarbamate in the treatment of patients with obstructive diseases of the peripheral arteries.
    Zelikovsky A; Urca I; Shaklai M; de Vries A
    Jpn Heart J; 1973 Jan; 14(1):12-21. PubMed ID: 4541560
    [No Abstract]   [Full Text] [Related]  

  • 7. [The pyridinolcarbamate-clofibrate combination in the treatment of vascular diseases in diabetics].
    Parodi FA; Caputo G
    Clin Ter; 1976 Dec; 79(6):571-81. PubMed ID: 1009761
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of an infusion of piribedil in normal subjects and in patients with peripheral obliterating arterial disease on the blood flow of the lower limbs and on blood, plasma and serum viscosity].
    Forconi S; Guerrini M; Agnusdei D; Di Perri T
    Minerva Med; 1976 May; 67(25):1671-80. PubMed ID: 934519
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rheographic normalization in prediabetic subjects treated with pyridinolcarbamate].
    Furitano G; Paterna S; Di Pasquale P
    Minerva Med; 1978 May; 69(24):1655-9. PubMed ID: 662168
    [No Abstract]   [Full Text] [Related]  

  • 11. [Changes of the blood kallikrein-kinin system in patients with diffuse toxic goiter under the influence of thyrostatic therapy and prodectin].
    Matiashina GI
    Vrach Delo; 1989 Apr; (4):31-3. PubMed ID: 2474220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiatherogenic effect of pyridinolcarbamate (prodectin). Experimental study.
    Orbetzova V; Jurukova Z; Orbetzova M
    Artery; 1980; 8(6):560-9. PubMed ID: 7259535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 14. [Effects of the administration of buflomedil-hydrochloride on the arterial circulation of the legs in patients with obliterative arteriopathies].
    Tallarida G; Baldoni F; Peruzzi G; Raimondi G; Grimaldi I; Visigalli G; Gristina S; Massaro M; De Martinis L; Sangiorgi M
    Cardiologia; 1983 Aug; 28(8):651-60. PubMed ID: 6687209
    [No Abstract]   [Full Text] [Related]  

  • 15. [Current trends in medical treatment of obliterating arteriopathies of the limbs].
    Pratesi F; Caramelli L; Deidda C; Nuti A; Tesi M
    Recenti Prog Med; 1973 Aug; 55(2):163-90. PubMed ID: 4148951
    [No Abstract]   [Full Text] [Related]  

  • 16. [Regional hemodynamic changes induced by muscular exercise in subjects with obliterating arteriopathy of the lower extremities: effect of beta receptor blocking].
    Brevetti G; Paudice G; Lavecchia G; De Caprio L; Ferro G; D'Ascia C; Orefice U
    Boll Soc Ital Cardiol; 1977; 22(7):1094-100. PubMed ID: 36115
    [No Abstract]   [Full Text] [Related]  

  • 17. [Prodectin in the treatment of viral hepatitis].
    Kozhukhova EA; Iakushin AI; Zakharova VI; Mebel' BD; Larionov GM
    Sov Med; 1983; (10):96-7. PubMed ID: 6658556
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prodectin treatment of partial hearing loss as a result of atherosclerosis].
    Smirnova NA; Timakov VA; Mikushkin MK
    Vestn Otorinolaringol; 1982; (6):53-6. PubMed ID: 7179649
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of prodectin in the treatment of cerebral arteriosclerosis and its complications.
    Abrányi I; Máté
    Ther Hung; 1976; 24(1):20-3. PubMed ID: 790631
    [No Abstract]   [Full Text] [Related]  

  • 20. [Effect of prodectin on the activity of the blood kallikrein-kinin system in diffuse toxic goiter].
    Oleĭnik VA; Matiashina GI
    Probl Endokrinol (Mosk); 1986; 32(4):7-10. PubMed ID: 3639497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.